% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Bender:278376,
      author       = {K. Bender and J. Kahn and E. Perez and F. Ehret$^*$ and S.
                      Roohani and D. Capper$^*$ and S. Schmid and D. Kaul$^*$},
      title        = {{D}iffuse paediatric-type high-grade glioma, {H}3-wildtype
                      and {IDH}-wildtype: case series of a new entity.},
      journal      = {Brain tumor pathology},
      volume       = {40},
      number       = {4},
      issn         = {1433-7398},
      address      = {Tōkyō},
      publisher    = {Springer},
      reportid     = {DKFZ-2023-01626},
      pages        = {204-214},
      year         = {2023},
      note         = {2023 Oct;40(4):204-214},
      abstract     = {Diffuse paediatric-type high-grade glioma, H3-wildtype and
                      IDH-wildtype (pHGG) is a rare and aggressive brain tumor
                      characterized by a specific DNA methylation profile. It was
                      recently introduced in the 5th World Health Organization
                      classification of central nervous system tumors of 2021.
                      Clinical data on this tumor is scarce. This is a case
                      series, which presents the first clinical experience with
                      this entity. We compiled a retrospective case series on pHGG
                      patients treated between 2015 and 2022 at our institution.
                      Data collected include patients' clinical course, surgical
                      procedure, histopathology, genome-wide DNA methylation
                      analysis, imaging and adjuvant therapy. Eight pHGG were
                      identified, ranging in age from 8 to 71 years. On MRI tumors
                      presented with an unspecific intensity profile, T1w hypo- to
                      isointense and T2w hyperintense, with inhomogeneous contrast
                      enhancement, often with rim enhancement. Three patients died
                      of the disease, with overall survival of 19, 28 and 30
                      months. Four patients were alive at the time of the last
                      follow-up, 4, 5, 6 and 79 months after the initial surgery.
                      One patient was lost to follow-up. Findings indicate that
                      pHGG prevalence might be underestimated in the elderly
                      population.},
      keywords     = {Case series (Other) / Diffuse paediatric-type high-grade
                      glioma (Other) / H3-wildtype (Other) / IDH-wildtype (Other)
                      / pHGG (Other)},
      cin          = {BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37561227},
      doi          = {10.1007/s10014-023-00468-3},
      url          = {https://inrepo02.dkfz.de/record/278376},
}